Compare Enveric Biosciences Inc (ENVB) vs Invesco Ltd. (IVZ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Enveric Biosciences Inc vs Invesco Ltd. — how do they compare? Enveric Biosciences Inc trades at $1.42 (market cap $5.32M), while Invesco Ltd. trades at $30.33 (market cap $13.43B). The key difference: Invesco Ltd. is far larger — about 2524.4× Enveric Biosciences Inc's market cap, and Invesco Ltd. pays a 2.84% dividend while Enveric Biosciences Inc pays none. Which is the better fit depends on your goals.
| ENVB | IVZ | |
|---|---|---|
Market Cap | $5.32M | $13.43B |
Sector | Health | Financials |
52-Week High | $17.40 | $30.30 |
52-Week Low | $1.28 | $16.88 |
Enterprise Value | $408.82K | $23.68B |
Dividend Yield | — | 2.84% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ENVB trades at $1.41, up 6.82% in the last session. The stock shows a bearish technical trend with moving averages signaling sell, but oscillators are neutral. Financially, the company reported a net loss of $8.77M for 2025, with negative ROE and ROA, though it consistently beat EPS expectations. Recent news highlights participation in investor conferences and progress with its neuroplastogen candidate EB-003.
Outlook is speculative with high risk due to negative profitability and cash burn, offset by strong analyst buy ratings (75%) and positive clinical updates. Key risks include funding needs and drug development hurdles, while catalysts hinge on regulatory milestones and partnership news.
Invesco (IVZ) trades at $30.50, up 6.16% in the past 24 hours, with a bullish technical signal from moving averages. The company reported mixed earnings, beating estimates in Q3 and Q4 2025 but missing in Q1 2026. Revenue grew to $6.38 billion in 2025, though net income remained negative at -$281.70 million. Analyst consensus is divided with 12 buys and 16 holds, targeting $30.50 on average. Recent news highlights dividend declarations and AUM growth to $2.47 trillion as of June 2026.
The outlook for IVZ is cautiously optimistic, supported by strong cash flow from operations and upward earnings revisions. Key risks include persistent negative profit margins and competitive pressures in asset management. Upside potential hinges on execution improvements and market sentiment shifts, with the current price near the consensus target suggesting limited near-term movement.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Enveric Biosciences Inc
Enveric Biosciences is a biotechnology company focused on developing next-generation psychedelic-inspired therapies for mental health and neuropsychiatric disorders.
Read more on ENVB →About Invesco Ltd.
Invesco provides investment-management services to retail (65% of managed assets) and institutional (35%) clients. At the end of August 2022, the firm had $1.416 trillion in assets under management spread among its equity (47% of AUM), balanced (5%), fixed-income (22%), alternative investment (14%), and money market (12%) operations. Passive products account for 32% of Invesco's total AUM, including 56% of the company's equity operations and 13% of its fixed-income platform. Invesco's U.S. retail business is one of the 10 largest nonproprietary fund complexes in the country. The firm also has a meaningful presence outside the U.S., with close to one third of its AUM sourced from Canada (2%), the U.K. (4%), continental Europe (11%), and Asia (15%).
Read more on IVZ →
